The search results contain references to "PmiR2" in the context of BLIMP1 (B-lymphocyte-induced maturation protein 1) knockdown experiments in lymphoma research . Here, "PmiR2" refers to a short hairpin RNA (shRNA) construct targeting BLIMP1, not an antibody. This construct was used to study BLIMP1's role in regulating EZH2 (enhancer of zeste homolog 2) expression and its impact on cell survival .
While "PMIR2 Antibody" is unverified, several mitochondrial and metabolic antibodies are highlighted in the sources:
AMA-M2 antibodies target mitochondrial pyruvate dehydrogenase complexes (PDC-E2) and are diagnostic markers for primary biliary cholangitis (PBC) .
Specificity and clinical relevance of AMA subtypes correlate with disease progression and prognosis .
| AMA-M2 Subtype | Clinical Association | Sensitivity (%) | Specificity (%) |
|---|---|---|---|
| Anti-PDC-E2 | PBC Diagnosis | 90–95 | >99 |
| Multi-specific AMA | Early PBC Detection | 70–85 | 95 |
Targets pyruvate kinase M1/2 isoforms (PKM1 and PKM2), key enzymes in glycolysis .
Validated in glioblastoma, lung carcinoma, and hepatocellular carcinoma cell lines via Western blot and immunofluorescence .
Studies emphasize challenges in monoclonal antibody specificity, with ~30% of commercial antibodies exhibiting unintended polyspecificity . Recombinant antibodies are recommended for improved reproducibility and reduced cross-reactivity .
PyIgClassify: Catalogues antibody CDR structures and T-cell receptor data .
Histone Antibody Specificity Database: Evaluates histone modification antibodies via peptide microarrays .
Antibody Therapeutics Database: Lists FDA-approved antibodies, including engineering details (e.g., Fc mutations for half-life extension) .
PMIR2 Antibody may represent a typographical error, novel/unpublished reagent, or proprietary compound not yet indexed in public databases.
Suggested actions: